ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 647

Gene Expression in Cellular Subsets in Psoriatic Disease

Anastasiya Muntyanu1, Fatima Abji2, Remy Pollock1, Vinod Chandran2 and Dafna D Gladman2, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Gene Expression, psoriasis and psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriatic arthritis is an inflammatory musculoskeletal disease which develops in 30% of patients with psoriasis. Our previous peripheral blood microarray study identified CXCL10, NOTCH2NL, HAT1, and SETD2 as differentially expressed between PsA and psoriasis patients without arthritis (PsC). This study aimed to determine gene expression in leukocyte subsets to elucidate their functions in psoriatic disease.

Methods: Peripheral blood mononuclear cells were isolated using Ficoll paque separation from PsA and PsC patients not receiving biologic therapy and healthy controls (HC). T cells (CD3+), monocytes (CD14+), and NK cells (CD56+) were separated by positive selection. mRNA was extracted using RNeasy miniprep kits and qPCR performed with 75ng mRNA to determine CXCL10, CXCR3, NOTCH2NL, IL-17A, HAT1, and SETD2 gene expression. A two-way ANOVA with Bonferroni’s post-hoc test was used to determine significant differences (p<0.05).

Results: Gene expression was measured in 15 PsA (mean age 59, 60% males), 15 PsC (mean age 57, 67% males), and HC (mean age 54, 60% males). Expression of IL-17A in monocytes was 18.42-fold greater in PsA patients than PsC (p<0.0001) and 31.36-fold greater in PsA than HCs (p<0.0001). There were no other significant differences in gene expression between disease groups in each given cell type. However, in T cells, CXCL10 was elevated in PsA compared to PsC (1.42-fold) and HC (2.47-fold). A similar trend was found for the receptor, CXCR3, where expression was higher in PsA than PsC (1.18-fold) and HC (1.13-fold). Finally, SETD2 expression in PsA was higher than PsC (1.65-fold) and HC (1.28-fold) in T cells. CXCL10 expression in monocytes (p<0.0001; 11.1-fold) and NK cells (p<0.0001; 2.04-fold) was higher than in T cells. Expression of CXCR3 was higher in T cells compared to monocytes (p<0.0001; 208.17-fold) and NK cells (p<0.0001; 1.3-fold). HAT1 was more highly expressed in T cells as compared to monocytes (p=0.0003; 3.41-fold) and NK cells (p=0.0274; 1.48-fold). Expression of SETD2 was elevated in T cells compared to monocytes (p=0.0007; 3.2-fold) and NK cells (p=0.0082; 1.22-fold). NOTCH2NL expression was elevated in T cells compared to monocytes (p=0.0154; 2.43-fold).

Conclusion: Genes of interest were differentially expressed in leukocyte subsets. The higher expression of these genes in PsA compared to PsC and HCs could provide insight into their role in driving the development of PsA. Knowing which cell types are predominantly involved with expression of certain biomarkers will aid in developing targeted treatments.


Disclosure: A. Muntyanu, None; F. Abji, None; R. Pollock, None; V. Chandran, None; D. D. Gladman, None.

To cite this abstract in AMA style:

Muntyanu A, Abji F, Pollock R, Chandran V, Gladman DD. Gene Expression in Cellular Subsets in Psoriatic Disease [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/gene-expression-in-cellular-subsets-in-psoriatic-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gene-expression-in-cellular-subsets-in-psoriatic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology